相关实验视频

Updated: May 6, 2026

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica

Published on: October 28, 2022

英格诺尔通过准PTGS2/PI3K/AKT信号轴来改善化:对治疗干预的影响

Yifan Jing¹, Ying Bai², Chao Liang¹

¹Department of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan City, China; Anhui Province Engineering Laboratory of Occupational Health and Safety, School of Medicine, Anhui University of Science and Technology, Huainan City, China.

Cellular signalling

|March 30, 2025

概括

植物衍生化合物Ingenol,通过减少肺炎和纤维化,在治疗症方面表现有前途. 它通过抑制PTGS2/PI3K/AKT通路而起作用,为这种不可逆转的肺部疾病提供了潜在的新疗法.

科学领域:

肺部医学肺部医学
药理学药理学是指药理学的学科.
毒理学毒理学毒理学

背景情况:

病是一种不可逆转的肺部疾病,由吸入粉引起,导致炎症和纤维化.
病的确切原因尚不清楚,这限制了有效的治疗选择.
恩格诺是来自Euphorbiaceae植物的类化合物,具有抗炎和抗病毒的特性.

研究的目的:

调查 Ingenol 在改善二氧化诱导的症方面的潜力.
为了阐明 Ingenol 治疗效果的潜在分子机制.

主要方法:

在体内研究,使用小鼠模型的化物诱导的化物.
在体外实验中评估细胞对 Ingenol 的反应.
生物信息学和网络药理学分析以确定分子标.

主要成果:

在小鼠中,Ingenol显著改善了呼吸功能,并减少了肺炎和纤维化.
在体外, Ingenol 抑制了促炎因素,巨细胞亡和纤维细胞迁移.
已证实 ingenol 能调节 PTGS2/PI3K/AKT 信号通路.

结论:

英格诺尔通过抑制PTGS2/PI3K/AKT通路,有效地改善了病.
英格诺尔证明了其作为治疗病的治疗剂的潜力.
需要进一步研究 Ingenol 对症治疗的疗效和安全性.

关键词:

纤维化纤维化纤维化炎症炎症是一种炎症.没有任何的东西.这是PTGS2的PTGS2.化是一种化.

更多相关视频

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

Published on: January 6, 2023

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...